ライフサイエンスコーパス: coronary angioplasty

1 atients undergoing percutaneous transluminal coronary angioplasty).

2 t occurs following percutaneous transluminal coronary angioplasty.

3 al delivery of cytochalasin B at the site of coronary angioplasty.

4 s in patients with previous restenosis after coronary angioplasty.

5 Twenty-three swine underwent multivessel coronary angioplasty.

6 d platelet activation and interaction during coronary angioplasty.

7 may contribute to an improved outcome after coronary angioplasty.

8 latelet adherence to leukocytes occurs after coronary angioplasty.

9 gnificantly higher acute costs compared with coronary angioplasty.

10 (CABG) surgery and percutaneous transluminal coronary angioplasty.

11 s in patients with previous restenosis after coronary angioplasty.

12 ss graft (CABG) or percutaneous transluminal coronary angioplasty.

13 30 days among patients undergoing high-risk coronary angioplasty.

14 ing transitory MIS in the setting of planned coronary angioplasty.

15 randomized to tirofiban or placebo following coronary angioplasty.

16 cell interactions may affect the outcome of coronary angioplasty.

17 ajor adverse cardiac events after successful coronary angioplasty.

18 lockers can reduce ischemic complications of coronary angioplasty.

19 receive either bivalirudin or heparin during coronary angioplasty.

20 ter outcomes for elderly patients undergoing coronary angioplasty.

21 ly (within 1 week) and late (>6 weeks) after coronary angioplasty.

22 cation that limits the long-term efficacy of coronary angioplasty.

23 ffects in animal models and in humans during coronary angioplasty.

24 FR <0.75 underwent percutaneous transluminal coronary angioplasty.

25 d optimized might be a beneficial adjunct to coronary angioplasty.

26 verall adverse late outcome after successful coronary angioplasty.

27 al coronary branch occlusion during elective coronary angioplasty.

28 bo sources in patients with restenosis after coronary angioplasty.

29 s graft surgery or percutaneous transluminal coronary angioplasty.

30 the short-term and the long-term outcomes of coronary angioplasty.

31 rrelated with the prevalence of percutaneous coronary angioplasty (-0.717; -0.787) and coronary arter

32 ngiography (19.2% versus 15.2%, P=.0001) and coronary angioplasty (11.6% versus 8.2%, P<.0001).

33 s was $3,268 higher than for those receiving coronary angioplasty ($14,802 vs. $11,534, p < 0.001).

34 patients, with the largest effect seen with coronary angioplasty (15% versus 20% for heparin, P=.04)

35 tion (57% versus 63% for heparin, P=.04) and coronary angioplasty (18% versus 22%, P=.08).

36 y angiography (67.1% versus 39.3%, P<.0001), coronary angioplasty (32.5% versus 13.2%, P<.0001), or c

37 ; reperfusion, using thrombolytic therapy or coronary angioplasty (67.2% [59.8%-75.1%]); prescription

38 s that occur after percutaneous transluminal coronary angioplasty, a widespread treatment for coronar

39 infarction, after percutaneous transluminal coronary angioplasty, after coronary artery bypass graft

40 better quality of life for three years than coronary angioplasty, after the initial morbidity caused

41 as clinical benefits beyond those of primary coronary angioplasty alone.

42 s have not shown convincing superiority over coronary angioplasty alone.

43 % (64% for balloon percutaneous transluminal coronary angioplasty and 33% for coronary stenting [P=0.

44 cations, physicians from hospitals providing coronary angioplasty and bypass surgery rated angiograph

45 ip between the time to treatment with direct coronary angioplasty and clinical outcome.

46 s measured by the prevalence of percutaneous coronary angioplasty and coronary artery bypass graft su

47 n procedure (i.e., percutaneous transluminal coronary angioplasty and coronary artery bypass graft su

48 Patients undergoing percutaneous coronary angioplasty and coronary artery bypass graft we

49 Before coronary angioplasty and heart surgery, these preconditi

50 f restenosis after percutaneous transluminal coronary angioplasty and in the progression of atheroscl

51 ive in reducing ischemic complications after coronary angioplasty and in unstable angina, making this

52 iators occur after percutaneous transluminal coronary angioplasty and may play a role in restenosis.

53 0% to 50% of vascular interventions, such as coronary angioplasty and peripheral vein grafting.

54 Currently, more than one million coronary angioplasty and stent implantation procedures a

55 risk in a cohort of 284 patients undergoing coronary angioplasty and stent placement (rs350099: TT v

56 ral angiography and 20 patients treated with coronary angioplasty and stent placement.

57 However, its effects after coronary angioplasty and the cellular mechanisms involve

58 s an important mechanism of restenosis after coronary angioplasty and the primary mechanism of resten

59 inistered by local delivery after successful coronary angioplasty and warrants further study of its e

60 scularization with percutaneous transluminal coronary angioplasty and/or coronary artery bypass graft

61 site facilities for cardiac catheterization, coronary angioplasty, and bypass surgery (similarly equi

62 mpared six and 12 month cumulative costs for coronary angioplasty- and stent-treated cohorts.

63 graft surgery and percutaneous transluminal coronary angioplasty are directed at more severe coronar

64 ypass grafting and percutaneous transluminal coronary angioplasty are now well established methods of

65 utcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months.

66 limited the clinical outcomes of multivessel coronary angioplasty before stents were available to imp

67 Percutaneous coronary angioplasty can be performed with low mortality

68 tionship for coronary artery bypass surgery, coronary angioplasty, carotid endarterectomy, other canc

69 y bypass grafting, percutaneous transluminal coronary angioplasty, carotid endarterectomy, reduction

70 rumentation with a percutaneous transluminal coronary angioplasty catheter advanced to the mid-left a

71 Restoration of disposable coronary angioplasty catheters using a highly controlled

72 nfatal MI, stroke, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or de

73 ardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft surge

74 cardiovascular event (myocardial infarction, coronary angioplasty, coronary artery bypass graft surge

75 tion (MI), stroke, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, or d

76 ardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, i

77 tegrins (abciximab; c7E3 Fab) at the time of coronary angioplasty decreases the need for repeat revas

78 rocedures included percutaneous transluminal coronary angioplasty, directional or rotational atherect

79 to short-term cognitive dysfunction, whereas coronary angioplasty does not.

80 graft surgery and percutaneous transluminal coronary angioplasty) during six month follow-up.

81 anisms and clinical results of excimer laser coronary angioplasty (ELCA) versus rotational atherectom

82 rvention: group 1 (percutaneous transluminal coronary angioplasty era), group 2 (early stent era), gr

83 an oral sirolimus-loading dose of 6 mg after coronary angioplasty, followed by 2 mg/d for 4 weeks.

84 1+/-10 years) who were on a waiting list for coronary angioplasty for a mean time of 4.8+/-2.4 months

85 outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI

86 dy was to determine predictors of successful coronary angioplasty for acute myocardial infarction (MI

87 tcome in diabetic patients undergoing direct coronary angioplasty for acute myocardial infarction.

88 mortality among diabetic patients undergoing coronary angioplasty for acute myocardial infarction.

89 n while undergoing percutaneous transluminal coronary angioplasty for single-vessel coronary artery d

90 ere measured in 20 patients before and after coronary angioplasty for stable angina at three sampling

91 mplications in high risk patients undergoing coronary angioplasty for thrombus-containing lesions det

92 schemic complications in patients undergoing coronary angioplasty for thrombus-containing lesions det

93 atients undergoing percutaneous transluminal coronary angioplasty from the period 1980 through 1989 t

94 Coronary angioplasty has a lower five-year cost than byp

95 Coronary angioplasty has numerous shortcomings.

96 us coronary bypass surgery, as compared with coronary angioplasty, has a highly favorable influence o

97 s studies have shown that women treated with coronary angioplasty have a higher incidence of procedur

98 Patients who undergo coronary angioplasty have a shorter convalescence than t

99 ass surgery, coronary artery bypass surgery, coronary angioplasty, heart transplantation, pediatric c

100 herapy, was associated with lower mortality (coronary angioplasty: HR 0.51, 95% CI 0.32 to 0.81; coro

101 mab bolus with infusion given at the time of coronary angioplasty improves outcomes as long as 3 year

102 not improve after percutaneous transluminal coronary angioplasty in > or = 50% of patients, postulat

103 f physicians and 25% of hospitals performing coronary angioplasty in 1992 were unlikely to have met t

104 utcomes after coronary bypass surgery versus coronary angioplasty in 525 patients with pharmacologica

105 ents who underwent percutaneous transluminal coronary angioplasty in BARI.

106 fficacy of primary percutaneous transluminal coronary angioplasty in patients with acute myocardial i

107 oplasty and reduce rates of restenosis after coronary angioplasty in selected patients.

108 ine both the time required to perform direct coronary angioplasty in the Global Use of Strategies to

109 is similar after coronary bypass surgery and coronary angioplasty in the majority of patients.

110 lloon angioplasty (percutaneous transluminal coronary angioplasty) in contemporary clinical practice.

111 disease: repeated balloon inflations before coronary angioplasty induce preconditioning-like effects

112 , 30 seconds PTCA [percutaneous transluminal coronary angioplasty] inflations/deflations)+PCI (n=65)

113 Restenosis after coronary angioplasty is a major limitation of an otherwi

114 monstrated 6 months after medical therapy or coronary angioplasty is a valuable prognostic marker in

115 Coronary angioplasty is an alternative revascularization

116 Percutaneous transluminal coronary angioplasty is an alternative to CABG for patie

117 on during elective percutaneous transluminal coronary angioplasty is associated with myocardial ische

118 clinical trials have shown that multivessel coronary angioplasty is feasible and provides similar lo

119 clusive disease by percutaneous transluminal coronary angioplasty is hampered by maladaptive wound he

120 Prophylactic percutaneous transluminal coronary angioplasty is one revascularization strategy e

121 Although the frequency of restenosis after coronary angioplasty is reduced by stenting, when resten

122 Whereas it is arguable whether coronary angioplasty is superior to thrombolytic therapy

123 grafts) underwent percutaneous transluminal coronary angioplasty, laser ablation, rotational atherec

124 ronaries underwent percutaneous transluminal coronary angioplasty, laser angioplasty, rotational athe

125 bypass grafting or percutaneous transluminal coronary angioplasty, <60 days after nuclear testing, th

126 undergo noncardiac surgery within 90days of coronary angioplasty may be at increased risk for postop

127 Other therapies, such as primary coronary angioplasty, may be preferable in patients with

128 cates was analyzed in 2,127 patients who had coronary angioplasty (mean age 57.6 years) without acute

129 Percutaneous transluminal coronary angioplasty (n = 10) was unsuccessful in two pa

130 received either coronary stent (n = 384) or coronary angioplasty (n = 159) and met eligibility crite

131 ndomized comparison of a strategy of initial coronary angioplasty (n = 198) or coronary bypass surger

132 Patients randomized to direct coronary angioplasty (n=565) were divided into groups ba

133 revascularization (percutaneous transluminal coronary angioplasty, n=20; coronary artery bypass surge

134 nd Blood Institute Percutaneous Transluminal Coronary Angioplasty (NHLBI PTCA) Registry.

135 Major complications of coronary angioplasty occur in 4% to 9% of patients.

136 Since the first coronary angioplasty on Sept 16, 1977, the field of perc

137 or the need for coronary revascularization (coronary angioplasty or bypass surgery).

138 ography (within 24 hours of shock onset) and coronary angioplasty or bypass surgery, if appropriate,

139 atients who underwent revascularization with coronary angioplasty or coronary artery bypass graft sur

140 atheterization and percutaneous transluminal coronary angioplasty or coronary artery bypass graft sur

141 revascularization (percutaneous transluminal coronary angioplasty or coronary artery bypass graft).

142 previous revascularization with percutaneous coronary angioplasty or coronary artery bypass grafting.

143 atients undergoing percutaneous transluminal coronary angioplasty or coronary stenting initially and

144 ications among patients undergoing high-risk coronary angioplasty or directional atherectomy but incr

145 iovascular events at both 2 and 7 days after coronary angioplasty or directional coronary atherectomy

146 ndom assignment to percutaneous transluminal coronary angioplasty or medical therapy in the Angioplas

147 erence in long-term results for freedom from coronary angioplasty or stenting, renal dysfunction, dia

148 , or angina, coronary artery bypass surgery, coronary angioplasty, or abnormal coronary angiographic

149 y bypass grafting, percutaneous transluminal coronary angioplasty, or angiographic evidence of signif

150 c catheterization, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting

151 (myocardial infarction, angina, percutaneous coronary angioplasty, or coronary artery bypass surgery)

152 artery bypass graft procedure, percutaneous coronary angioplasty, or CVD death) occurred during a me

153 y bypass grafting, percutaneous transluminal coronary angioplasty, or other revascularization), strok

154 , 95% confidence interval [CI] 0.24 to 0.58; coronary angioplasty: OR 0.60, 95% CI 0.25 to 1.49; coro

155 Although refinements have occurred in coronary angioplasty over the past decade, little is kno

156 y bypass graft and percutaneous transluminal coronary angioplasty (p<0.001 and p=0.005, respectively)

157 5% vs. 11.5% after percutaneous transluminal coronary angioplasty; p < 0.01).

158 cancer resection, cardiac valve replacement, coronary angioplasty, pancreatic cancer resection, and t

159 vascularization (9% vs. 26%, p = 0.001) than coronary angioplasty patients within six months of the p

160 s with multivessel percutaneous transluminal coronary angioplasty, patients who undergo multivessel s

161 Grafting' (CABG), 'percutaneous transluminal coronary angioplasty' (PCTA) and 'Other Coronary Heart D

162 The benefits of primary coronary angioplasty persisted when stratified by hospit

163 gn have made stent implantation the standard coronary angioplasty procedure.

164 -2.29), coronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35; 1.08-1.69),

165 nverse relation exists between the number of coronary angioplasty procedures performed by physicians

166 hat physicians who perform larger numbers of coronary angioplasty procedures will have better outcome

167 atheterization and percutaneous transluminal coronary angioplasty (PTCA) (ad hoc) in comparison with

168 are the outcome of percutaneous transluminal coronary angioplasty (PTCA) (n = 834) and coronary arter

169 in one branch and percutaneous transluminal coronary angioplasty (PTCA) (with or without atherectomy

170 ombolysis, primary percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infar

171 inical features of percutaneous transluminal coronary angioplasty (PTCA) after failed thrombolysis fo

172 ,154 patients with percutaneous transluminal coronary angioplasty (PTCA) alone, 876 patients with cor

173 fully managed with percutaneous transluminal coronary angioplasty (PTCA) alone.

174 obtained from 100 percutaneous transluminal coronary angioplasty (PTCA) and 75 cardiac surgical pati

175 ft surgery (CABG), percutaneous transluminal coronary angioplasty (PTCA) and cardiac catheterization

176 rm consequences of percutaneous transluminal coronary angioplasty (PTCA) and continued medical treatm

177 cularization using percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass (

178 The impact of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass g

179 etes after initial percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass g

180 Percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass g

181 appropriateness of percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass g

182 Institute (NHLBI) Percutaneous Transluminal Coronary Angioplasty (PTCA) and New Approaches to Corona

183 ontaneously before percutaneous transluminal coronary angioplasty (PTCA) and the likelihood of an isc

184 complication after percutaneous transluminal coronary angioplasty (PTCA) and to determine its clinica

185 risk of performing percutaneous transluminal coronary angioplasty (PTCA) at the time of diagnostic ca

186 gated the reuse of percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, restored

187 hospitals without percutaneous transluminal coronary angioplasty (PTCA) capability.

188 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) compared with thrombolytic t

189 bolytic therapy or percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarct

190 udy comparing intensive medical therapy with coronary angioplasty (PTCA) for suppression of myocardia

191 urgery (CABG) with percutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronar

192 Percutaneous transluminal coronary angioplasty (PTCA) has become the dominant trea

193 The term rescue percutaneous transluminal coronary angioplasty (PTCA) has been introduced to descr

194 tion after primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarcti

195 c therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarcti

196 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) in AMI include in-hospital r

197 s graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subset

198 ma formation after percutaneous transluminal coronary angioplasty (PTCA) in porcine coronary arteries

199 rterial wall after percutaneous transluminal coronary angioplasty (PTCA) induces thrombus formation a

200 Although percutaneous transluminal coronary angioplasty (PTCA) is a highly effective proced

201 surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) may be different in the pres

202 tudy applied the New York State conventional coronary angioplasty (PTCA) model of clinical outcomes t

203 ls for in-hospital percutaneous transluminal coronary angioplasty (PTCA) mortality on an independent

204 Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery restor

205 le swine underwent percutaneous transluminal coronary angioplasty (PTCA) of the left anterior descend

206 rimary stenting or percutaneous transluminal coronary angioplasty (PTCA) on health-related quality of

207 ho were undergoing percutaneous transluminal coronary angioplasty (PTCA) or CABG at Duke University M

208 ary arteriography, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass gr

209 scularization with percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass gr

210 mmendation was for percutaneous transluminal coronary angioplasty (PTCA) or for coronary artery bypas

211 ed to treatment by percutaneous transluminal coronary angioplasty (PTCA) or medical therapy, compared

212 omes after primary percutaneous transluminal coronary angioplasty (PTCA) or thrombolytic therapy for

213 eath after a first percutaneous transluminal coronary angioplasty (PTCA) procedure, in postmenopausal

214 ween the number of percutaneous transluminal coronary angioplasty (PTCA) procedures performed at hosp

215 nd 1993-1994 NHLBI Percutaneous Transluminal Coronary Angioplasty (PTCA) registries.

216 ith a "stent-like" percutaneous transluminal coronary angioplasty (PTCA) remains unknown.

217 economic impact of percutaneous transluminal coronary angioplasty (PTCA) revascularization salvage st

218 comes of a primary percutaneous transluminal coronary angioplasty (PTCA) strategy.

219 erial injury after percutaneous transluminal coronary angioplasty (PTCA) triggers acute thrombus form

220 laser-facilitated percutaneous transluminal coronary angioplasty (PTCA) versus "stand-alone" PTCA.

221 ndom assignment of percutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypas

222 A history of percutaneous transluminal coronary angioplasty (PTCA) was present in 35.4% of the

223 n (AMI) undergoing percutaneous transluminal coronary angioplasty (PTCA) with an optimal or "stent-li

224 angina undergoing percutaneous transluminal coronary angioplasty (PTCA) with predicted coronary arte

225 to compare primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy fo

226 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in

227 s grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), abdominal aortic aneurysm (

228 I), cardiac death, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass

229 c catheterization, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass

230 rpulsation (IABP), percutaneous transluminal coronary angioplasty (PTCA), and coronary bypass graft s

231 20 years, percutaneous transluminal balloon coronary angioplasty (PTCA), bare-metal stents (BMS), an

232 , as compared with percutaneous transluminal coronary angioplasty (PTCA), influences the prognosis in

233 s grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), or minimally invasive coron

234 hesis that primary percutaneous transluminal coronary angioplasty (PTCA), with subsequent discharge f

235 nd neointima formation limit the efficacy of coronary angioplasty (PTCA).

236 cular events after percutaneous transluminal coronary angioplasty (PTCA).

237 atients undergoing percutaneous transluminal coronary angioplasty (PTCA).

238 f restenosis after percutaneous transluminal coronary angioplasty (PTCA).

239 CABG) but not with percutaneous transluminal coronary angioplasty (PTCA).

240 cal outcomes after percutaneous transluminal coronary angioplasty (PTCA).

241 logical subset for percutaneous transluminal coronary angioplasty (PTCA).

242 omplications after percutaneous transluminal coronary angioplasty (PTCA).

243 r use in high-risk percutaneous transluminal coronary angioplasty (PTCA).

244 rafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).

245 ry reperfusion via percutaneous transluminal coronary angioplasty (PTCA).

246 d after adjunctive percutaneous transluminal coronary angioplasty (PTCA).

247 s occurring during percutaneous transluminal coronary angioplasty (PTCA).

248 atients undergoing percutaneous transluminal coronary angioplasty (PTCA).

249 y or after primary percutaneous transluminal coronary angioplasty (PTCA).

250 s in humans during percutaneous transluminal coronary angioplasty (PTCA).

251 nting (STENT), and percutaneous transluminal coronary angioplasty (PTCA).

252 ntral to the development of restenosis after coronary angioplasty (PTCA).

253 ntima formation that causes restenosis after coronary angioplasty (PTCA).

254 ndesired effect of percutaneous transluminal coronary angioplasty (PTCA).

255 ABG) compared with percutaneous transluminal coronary angioplasty (PTCA).

256 nary arteriography (cath-capable, 25.2%); 3) coronary angioplasty (PTCA-capable, 7.4%); and 4) bypass

257 er, they underwent percutaneous transluminal coronary angioplasty (PTCA; three 2-minute balloon infla

258 eath, nonfatal MI, percutaneous transluminal coronary angioplasty [PTCA] or coronary artery bypass gr

259 grafting [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) and renal transplantation a

260 alloon dilatation (percutaneous transluminal coronary angioplasty [PTCA]) for the treatment of in-ste

261 lloon angioplasty (percutaneous transluminal coronary angioplasty [PTCA]).

262 lloon angioplasty (percutaneous transluminal coronary angioplasty, PTCA) in the treatment of diffuse

263 rial injury (i.e., percutaneous transluminal coronary angioplasty, PTCA) is unknown.

264 Over 400,000 percutaneous transluminal coronary angioplasties (PTCAs) are currently performed a

265 New York's Coronary Angioplasty Registry was used to identify New Y

266 New York's coronary angioplasty registry was used to identify New Y

267 n, cardiac arrest, percutaneous transluminal coronary angioplasty, repeat CABG, and cardiac mortality

268 e analyzed data from the 1995 New York State Coronary Angioplasty Reporting System Registry to determ

269 Surgical and percutaneous transluminal coronary angioplasty revascularization performed before

270 signed 479 patients undergoing single-vessel coronary angioplasty routine stent implantation or initi

271 low-risk patients, percutaneous transluminal coronary angioplasty seems to control angina better than

272 Repetitive platelet accumulation at coronary angioplasty sites caused enhanced neointimal pr

273 inducing repetitive platelet aggregation at coronary angioplasty sites in dogs and measuring subsequ

274 ysis, conventional percutaneous transluminal coronary angioplasty, stenting, glycoprotein IIb/IIIa in

275 d the number of elective cardiac procedures (coronary angioplasty, stenting, or coronary bypass surge

276 likely to undergo percutaneous transluminal coronary angioplasty than other patients, whereas patien

277 disease achieve more symptomatic relief with coronary angioplasty than with medical therapy alone, bu

278 Restenosis is a serious complication of coronary angioplasty that involves the proliferation and

279 ials not involving percutaneous transluminal coronary angioplasty, the pooled effect size was -0.06 (

280 n trials involving percutaneous transluminal coronary angioplasty, the pooled relative risk of resten

281 ay, they underwent percutaneous transluminal coronary angioplasty (three 2-minute balloon inflations

282 IC), Evaluation of Percutaneous Transluminal Coronary Angioplasty to Improve Long-term Outcome of c7E

283 Heparin is administered during coronary angioplasty to prevent closure of the dilated v

284 bypass surgery or percutaneous transluminal coronary angioplasty, transmyocardial revascularization

285 s, including after percutaneous transluminal coronary angioplasty, unstable angina, stress-induced is

286 During coronary angioplasty, venous blood was obtained for flow

287 Percutaneous coronary angioplasty versus coronary artery bypass graft

288 o determine whether the results of the first Coronary Angioplasty Versus Excisional Atherectomy Trial

289 ients treated with percutaneous transluminal coronary angioplasty versus thrombolysis.

290 Coronary angioplasty was less likely to be performed whe

291 results when PTCA (percutaneous transluminal coronary angioplasty) was performed, complication rates,

292 ults on neointima formation at 4 weeks after coronary angioplasty were compared with the control grou

293 pass grafting, and percutaneous transluminal coronary angioplasty were higher in for-profit health pl

294 Forty patients undergoing successful coronary angioplasty were randomized into four equal gro

295 Twenty-two patients undergoing coronary angioplasty were randomized to an intracoronary

296 total of 2099 high-risk patients undergoing coronary angioplasty were randomized.

297 Randomized trials comparing coronary angioplasty with bypass surgery in patients wit

298 s may undergo medical treatment/observation, coronary angioplasty with stent deployment, or surgical

299 rocedures is performed as single or multiple coronary angioplasty with stenting using either bare met

300 l space would reduce luminal narrowing after coronary angioplasty without affecting systemic hemodyna